Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Ionis Pharmaceuticals $575 million convertible senior notes offering
The 1.75% convertible senior notes are due 2028
LifeScan Global refinancing and amendment to credit facilities
We advised an ad hoc group of term lenders in connection with the transaction
Oculis Holding $40.25 million debut equity offering
The shares are listed on the Nasdaq Global Market
TScan Therapeutics $140.6 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
Merck $6 billion revolving credit facility
We advised the agent, arrangers and lenders on the financing
Prospect Medical Holdings $375 million refinancing
We advised the administrative agent and collateral agent in connection with the existing ABL credit facility
Envision Healthcare and AmSurg chapter 11 restructuring
We are advising the administrative and collateral agent in connection with AmSurg’s restructuring
Coherus BioSciences $57.5 million follow-on offering
The stock is listed on the Nasdaq Global Market
Envision Healthcare chapter 11 restructuring
We are advising the administrative agent and collateral agent in connection with Envision Healthcare's restructuring
Emergent BioSolutions $150 million at-the-market offering
The shares are listed on the NYSE